Sun Pharma Advanced Research Company Ltd Shows Mixed Technical Signals Amid Price Momentum Shift

Feb 04 2026 08:04 AM IST
share
Share Via
Sun Pharma Advanced Research Company Ltd (SPARC) has experienced a notable shift in price momentum and technical indicators, reflecting a complex market sentiment. While some weekly and monthly indicators suggest mild bullishness, others remain bearish or neutral, signalling a cautious outlook for investors in the Pharmaceuticals & Biotechnology sector.
Sun Pharma Advanced Research Company Ltd Shows Mixed Technical Signals Amid Price Momentum Shift

Price Momentum and Recent Market Performance

SPARC’s current price stands at ₹139.50, marking a significant intraday high of ₹148.10 and a low of ₹137.40 on 4 Feb 2026. This represents a day change of 4.65%, reflecting renewed buying interest. The stock’s 52-week range remains wide, with a high of ₹204.25 and a low of ₹109.20, indicating considerable volatility over the past year.

Comparing returns with the broader Sensex index reveals a mixed performance. Over the past week, SPARC surged 13.00%, substantially outperforming the Sensex’s 2.30% gain. Over one month and year-to-date periods, the stock posted modest positive returns of 2.57% and 3.76%, respectively, while the Sensex declined by 2.36% and 1.74%. However, longer-term returns remain disappointing, with SPARC down 10.29% over one year and suffering steep losses of 28.94% and 26.46% over three and five years, respectively, contrasting sharply with the Sensex’s robust gains of 37.63% and 66.63% over the same periods. The ten-year return gap is even more pronounced, with SPARC down 50.92% versus the Sensex’s 245.70% rise.

Technical Trend Shift: From Bearish to Mildly Bearish

Technically, SPARC’s trend has shifted from outright bearish to mildly bearish, signalling a tentative improvement in market sentiment but still cautioning investors. The daily moving averages remain mildly bearish, suggesting that short-term price momentum has yet to fully recover. However, weekly and monthly indicators provide a more nuanced picture.

The Moving Average Convergence Divergence (MACD) indicator is mildly bullish on both weekly and monthly charts, indicating that momentum may be building gradually. This is supported by the Know Sure Thing (KST) oscillator, which also shows mild bullishness on weekly and monthly timeframes, hinting at a potential positive price trajectory if momentum sustains.

Strong fundamentals, steady climb upward! This Large Cap from Telecommunication sector earned its Reliable Performer badge through consistent execution. Safety meets solid returns here!

  • - Reliable Performer certified
  • - Consistent execution proven
  • - Large Cap safety pick

Get Safe Returns →

Mixed Signals from Momentum and Volume Indicators

The Relative Strength Index (RSI) remains neutral on both weekly and monthly charts, providing no clear signal of overbought or oversold conditions. This suggests that the stock is currently in a consolidation phase, with neither bulls nor bears dominating decisively.

Bollinger Bands present a contrasting view: weekly bands are bullish, indicating price strength and potential upward volatility, while monthly bands are mildly bearish, signalling caution over the longer term. This divergence underscores the importance of monitoring multiple timeframes for a comprehensive technical assessment.

Volume-based indicators add further complexity. The On-Balance Volume (OBV) is mildly bullish on the weekly chart, implying accumulation by investors in the short term. However, the monthly OBV is bearish, suggesting that longer-term selling pressure persists. This disparity may reflect institutional investors’ cautious stance amid broader market uncertainties.

Dow Theory and Moving Averages: Conflicting Trends

According to Dow Theory, the weekly trend is mildly bullish, indicating that the stock may be forming a base for a potential uptrend. Conversely, the monthly Dow Theory trend remains mildly bearish, reinforcing the longer-term cautionary tone.

Daily moving averages continue to show a mildly bearish stance, with the stock price hovering near key support levels. This suggests that while short-term momentum is improving, SPARC has yet to break decisively above critical resistance points to confirm a sustained uptrend.

Mojo Score and Market Capitalisation Grade

SPARC’s current Mojo Score stands at 6.0, reflecting a Strong Sell rating, an upgrade from the previous Sell grade as of 1 Feb 2024. This rating incorporates a comprehensive analysis of technical, fundamental, and market factors, signalling that despite recent positive momentum, the stock remains a cautious proposition for investors.

The company’s Market Cap Grade is 3, indicating a mid-tier market capitalisation relative to its peers in the Pharmaceuticals & Biotechnology sector. This grade suggests moderate liquidity and market interest but also highlights the need for careful risk management given the stock’s volatility.

Holding Sun Pharma Advanced Research Company Ltd from Pharmaceuticals & Biotechnology? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!

  • - Peer comparison ready
  • - Superior options identified
  • - Cross market-cap analysis

Switch to Better Options →

Investor Takeaway: Cautious Optimism Amid Mixed Technicals

Sun Pharma Advanced Research Company Ltd’s recent price momentum and technical indicator shifts suggest a tentative improvement in market sentiment, particularly on weekly timeframes. Mildly bullish MACD and KST readings, combined with a weekly bullish Bollinger Band and Dow Theory signals, point to potential upside if momentum sustains.

However, the persistent mildly bearish daily moving averages, neutral RSI, and bearish monthly OBV and Dow Theory trends counsel caution. The stock’s long-term underperformance relative to the Sensex and its Strong Sell Mojo Grade reinforce the need for disciplined risk management.

Investors should closely monitor key technical levels and volume trends for confirmation of a sustained uptrend before committing significant capital. Given the mixed signals, a balanced approach favouring partial exposure or hedging strategies may be prudent in the current environment.

Overall, SPARC remains a stock with potential for recovery but also notable risks, reflecting the broader challenges facing the Pharmaceuticals & Biotechnology sector amid evolving market dynamics.

{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News